Multiple hybrid and generic medicines were granted positive opinions by the European Medicines Agency’s Committee for Medicinal Products for Human Use at its September meeting, with these recommendations to grant European marketing authorizations coming on top of a similar nod for Stada and Xbrane’s Ximluci (ranibizumab) biosimilar rival to Lucentis (see sidebar).
Sun Pharmaceutical Industries received a positive CHMP opinion for its version of osteoporosis treatment Forsteo (teriparatide). However, unlike certain other...



